Full-Time
Executive Director
Confirmed live in the last 24 hours
Develops next-generation immuno-oncology therapies
Compensation Overview
$250,000 - $290,000Annually
Senior, Expert
San Carlos, CA, USA
- BA/BS in Business with an emphasis in economics, finance or mathematics; MBA is preferred.
- 7 10 years of experience in biopharma investment banking or corporate finance.
- Demonstrated high level of leadership and managerial skills.
- Demonstrated extensive background in biopharma corporate finance.
- Excellent interpersonal and communication skills.
- Must be able to thrive in a fast-paced, dynamic setting.
- Must have excellent corporate financial model skills with the ability to build complex and dynamic financial models and to iterate scenario models rapidly.
- Must have excellent MS PowerPoint skills.
- Occasional travel (10%) required.
- Building relevant models in partnership with colleagues from financial planning and senior leadership, to help inform corporate strategic decisions. Scenario modeling includes (but is not exclusive to): Product NPVs, Corporate development deal modeling, Financial product offerings (IRR or NPV), Long range plan P&L impact, Long range plan cash flow impact
- Developing executive level financial impact framing, analytics and communication with internal and external audiences, including the Board of Directors, Partners, and Investors
- Coordinating necessary cross-functional inputs from R&D, Commercial, Legal, Corporate Development, and Finance
- Evaluating capital requirements for the Company’s growth strategies
- Partnering cross functionally to evaluate all financial aspects of existing and prospective corporate partnerships
- Supporting Finance/Financial Planning as needed with LRP and budgeting process to support corporate goals and objectives
- Tracking critical issues/key milestones as they arise throughout the organization, with an understanding of their potential impact to the financial strategy
- Tracking current market and industry trends, regulations and policies, and advise on their impact on Corporate Financial Strategy
- Travel as required, both domestically and internationally, to support financial strategy objectives and activities
With an emphasis on immuno-oncology and cutting-edge therapies, this company stands out in the biotechnology industry for its dedicated approach to cancer treatment and improving patient outcomes. The development and FDA-approval of cutting-edge treatments like toripalimab-tpzi underscore its role as a leader in oncology research. Its focus on next-generation therapies and a differentiated PD-1 inhibitor highlights the company's commitment to both innovation and tangible results in healthcare.
Company Stage
IPO
Total Funding
$1.2B
Headquarters
Redwood City, California
Founded
2010
6 month growth
↓ -6%1 year growth
↓ -6%2 year growth
↓ -6%Benefits
Competitive base salary
Target bonus based on performance
stock options
Medical, dental, & vision coverage
PTO
401(k) plan
FSA